Business Wire

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines

Share

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England.

This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to eligible patients within the next few weeks.

The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include people ages 18 years and older who have the R117H mutation and those patients ages 12 months and older who have one of the nine licensed gating mutations.

“We are pleased that the nearly 280 eligible cystic fibrosis patients in Northern Ireland will soon have access to CFTR modulators to treat the underlying cause of their disease and we thank the authorities in Northern Ireland for their collaboration and commitment in this agreement,” said Ludovic Fenaux, Senior Vice President, Vertex International.

About CF in the UK
Over 10,000 people in the UK have CF — the second highest number in the world. Nearly 480 people in Northern Ireland have CF. CF is a debilitating, life-shortening inherited condition that causes progressive damage to organs across the body from birth. Currently, there is no cure for CF and half of people in the UK with CF die before they are 32. The daily impact of treatment is significant. It can take up to four or more hours, involving nebulizers, physiotherapy and up to 70 tablets a day. CF accounts for 9,500 hospital admissions and over 100,000 hospital bed days a year. A third of these are used by children under 15.

About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

SYMKEVI is indicated for people with CF ages 12 and older who either have two copies of the F508del mutation or one copy of the F508del mutation and have one of the following 14 mutations in which the CFTR protein shows residual function: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, or 3849+10kbC→T.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About KALYDECO® (ivacaftor)
KALYDECO® (ivacaftor) is the first medicine to treat the underlying cause of CF in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to keep CFTR proteins at the cell surface open longer to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.

KALYDECO is indicated in people ages 12 months and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. KALYDECO is also indicated for the treatment of patients with CF ages 18 years and older who have an R117H mutation in the CFTR gene.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has four approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements by Mr. Fenaux in the fourth paragraph of this press release and statements regarding our expectations for the patient populations that will be able to access Vertex’s medicines and the timing of such access. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

Vertex Pharmaceuticals Incorporated
UK Media: +44 20 3204 5275
MediaInfo@vrtx.com

U.S. Media: 617-341-6992
MediaInfo@vrtx.com

Investors: 617-961-7163
InvestorInfo@vrtx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Display Commercializes New, Variable Refresh Rate Technology for Increasing Smartphone Power Savings12.8.2020 11:19:00 EESTPress release

Samsung Display Company today revealed new display technology that features a remarkable power-saving function for mobile electronics, being commercialized for the first time in Galaxy Note 20 Ultra 5G flagship smartphones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005278/en/ Engineers from Samsung Display are using testing devices to inspect frequency changes in display panels that feature adaptive frequency technology (Photo: Business Wire) The display company has now successfully commercialized its low-power OLED adaptive frequency technology, which can curtail the operating power of a phone’s display by as much as 22 percent over existing smartphones now in general use. “High-definition video streaming and gaming are expanding their capabilities in line with 5G commercialization, creating a widespread need for display panel technologies that can enable greater power savings,” said Ho-Jung Lee, Vice President o

Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives12.8.2020 11:00:00 EESTPress release

Enterprises can now reduce cyber risk and secure their digital transformation initiatives in new markets including Blockchain, Cloud, DevOps, IoT and Code Signing as Thales unveils an expansion of its data protection ecosystem to more than 300 technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005038/en/ (Photo : Thales) Through these expanded technology integrations, which now include more than 500 IT products and services, Thales is enabling more organisations to integrate its data encryption, hardware security modules, key management and access management technologies with their existing IT infrastructure and cloud services to protect applications, data and identities. This will empower organisations to implement centralised data protection and access management controls for the whole customer journey. “The use of the cloud and digital transformation is now the cornerstone of any modern company,” sa

Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S.12.8.2020 03:00:00 EESTPress release

Celltrion Group (KRX:068270) today announced the launch of two rapid kits for SARS-CoV-2 in the US by the third week of August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005863/en/ SAMPINUTE™ COVID-19 Antigen MIA (left) and DiaTrust™ COVID-19 IgG/IgM Rapid Test (Photo: Business Wire) SAMPINUTETM COVID-19 Antigen MIA is an electrochemical immunoassay test for detection of SARS-CoV-2 antigen from nasopharyngeal swab samples, composed of one time use test cartridges and a portable analyzer developed in collaboration with BBB1. DiaTrustTM COVID-19 IgG/IgM Rapid Test is a one-step in-vitro diagnostic test based on immunochromatographic assay designed for the rapid detection of antibodies of the novel coronavirus in healthcare settings in collaboration with Humasis2. Both SAMPINUTETM COVID-19 Antigen MIA (antigen test) and DiaTrustTM COVID-19 IgG/IgM Rapid Test (antibody test) have shown reliable performance and promisi

Moody’s Acquires Stake in MARC, Strengthening Presence in Key ASEAN Market12.8.2020 02:00:00 EESTPress release

Moody’s Corporation (NYSE:MCO) announced today that it has acquired a minority stake in Malaysian Rating Corporation Berhad (MARC), a credit rating agency serving the Malaysian domestic bond and sukuk markets. The investment strengthens Moody’s presence in Southeast Asia and across domestic bond markets globally, and advances its position as a leader in Islamic finance. Based in Kuala Lumpur, MARC covers corporates and financial institutions, with key strengths in infrastructure and project finance. In addition to its rating services, MARC provides economic and fixed-income research, credit risk solutions, sustainability-linked offerings and finance-related online training programs. “Malaysia’s robust domestic bond market presents an attractive opportunity for Moody’s, and we are excited to build upon our partnership with MARC and its growing portfolio of ratings and services,” said Wendy Cheong, Managing Director and Head of Moody’s Investors Service Asia Pacific. The investment stren

Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry11.8.2020 16:38:00 EESTPress release

Following the signing of Bill No. 2285-d by President Volodymyr Zelenskyi to legalise the gambling industry in Ukraine, Parimatch, the international betting and technology company, has confirmed it will be bidding for the new operating licences in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005562/en/ Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry (Graphic: Business Wire) Parimatch was founded in Ukraine in 1994 and was amongst the first bookmakers in the CIS region to transition into a digital betting platform. Today, Parimatch has expanded internationally to become a global betting and technology brand. The company now looks to build on its heritage to become the largest and most innovative operator in its home market. Commenting on today’s signing, Sergey Portnov, CEO of Parimatch said: “I would firstly like to congratulate President Zelenskyi for delivering on his

Andersen Global Enhances Africa Platform With the Addition of Law Firm in Gabon11.8.2020 16:30:00 EESTPress release

Further strengthening its global platform and adding breadth to its regional footprint in Central Africa, Andersen Global announces its expansion into Gabon through a Collaboration Agreement with Libreville-based Business & Law Consulting (B & Law Consulting). The law firm, founded in 2017, is composed of more than 10 professionals who advise businesses in the areas of contract, corporate, commercial, tax, international trade, employments and general business law. “We are devoted to providing our clients with best-in-class solutions and maintain transparency and independence when handling client matters,” Managing Partner Khadidjatou Boussougou said. “Collaborating with Andersen Global is a great opportunity for us to continue to build our momentum and improve the quality of the services offered to our clients at an international level.” Andersen Global Chairman and Andersen CEO Mark Vorsatz said, “I am impressed with the level of efficiency and enthusiasm that B & Law Consulting demon

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom